paclitaxel

¿Es la litotricia coronaria tan efectiva como la aterectomía rotacional?

ROTACUT Study: Rotational Atherectomy with Cutting Balloon for Stent Expansion Optimization

Approximately 30% of patients undergoing percutaneous coronary intervention (PCI) present moderate to severe calcified lesions, which presents a significant challenge involving a high incidence of major adverse cardiovascular events (MACE). Rotational atherectomy (RA) is used to modify these calcified lesions and facilitate balloon angioplasty followed by stent implantation. The combination of RA with other plaque<a href="https://solaci.org/en/2023/11/30/rotacut-study-rotational-atherectomy-with-cutting-balloon-for-stent-expansion-optimization/" title="Read more" >...</a>

¿Debemos utilizar balones liberadores de droga en pacientes con enfermedad de múltiples vasos?

Stentless Strategy in ACS: Perfusion and Drug Coated Balloons

The initial strategy for the treatment of patients at high risk of bleeding (HBR) after percutaneous coronary intervention (PCI) has consisted of a short dual antiaggregation therapy (DAPT). Stents continue to improve, which has allowed the reduction of DAPT schemes and therefore the incidence of bleeding.&nbsp; However, researchers are also looking into another strategy to<a href="https://solaci.org/en/2023/11/22/stentless-strategy-in-acs-perfusion-and-drug-coated-balloons/" title="Read more" >...</a>

Nuevas estrategias en el territorio femoropoplíteo

Low vs High Dose Drug Coated Balloons in Femoropopliteal Territory

The use of drub coated balloons (DCB) in the treatment of femoropopliteal artery disease has grown. Studies on first generation high dose DCB (HD-DCB) have shown benefits, which has led to their recommendation by current guidelines. However, there have been reports of secondary effects caused by paclitaxel and its excipients.&nbsp; Second generation low dose DCB<a href="https://solaci.org/en/2023/11/02/low-vs-high-dose-drug-coated-balloons-in-femoropopliteal-territory/" title="Read more" >...</a>

TCT 2023 | ALIGN AR trial

TCT 2023 | COMPARE 60/80 HBR TRIAL

This was a randomized study including patients at high risk of bleeding treated with short dual antiplatelet therapy (DAPT).&nbsp; A total 747 patients were recruited, 368 received PCI with the ultrathin Superflex stent with 60 µm struts (SUF), and 364 received the Terumo Tansei with 89 µm struts (SF). Primary end point was NACE at<a href="https://solaci.org/en/2023/10/30/tct-2023-compare-60-80-hbr-trial-2/" title="Read more" >...</a>

Resultados del estudio COMPARE a 2 años: Balones cubiertos de Paclitaxel con bajas dosis vs altas dosis

Ultrathin Stents Shown Safe and Effective in Real World Patients

Ultrathin drug eluting stents (60 µm) had been shown beneficial vs. thin-strut stents in terms of target lesion failure (TLF) at 2, 3 and 5 years in randomized studies, but they had not been yet assessed in “real world” patients.&nbsp; The BIOFLOW VII is a prospective, multicenter study including 556 “real world”patients with a total<a href="https://solaci.org/en/2023/10/19/ultrathin-stents-shown-safe-and-effective-in-real-world-patients/" title="Read more" >...</a>

TAVI: Balón expandible o autoexpandible ¿Cuál es la respuesta?

Use of Drug-Coated Balloons in De Novo Lesions in Large Coronary Vessels

Drug-coated balloon (DCB) angioplasty is emerging as a novel treatment for coronary artery disease. Studies evaluating this strategy have demonstrated clinically non-inferior outcomes compared with those of drug-eluting stent (DES) implantation in patients with in-stent restenosis and de novo disease in small vessels. However, evidence for the use of DCBs in large coronary vessels is<a href="https://solaci.org/en/2023/09/28/use-of-drug-coated-balloons-in-de-novo-lesions-in-large-coronary-vessels/" title="Read more" >...</a>

stent-liberador-drogas-sirolimus-everolimus

EASTBOURNE Registry: Use of Sirolimus-Coated Balloons in Coronary Artery Disease

The introduction of drug coated balloons (DCB) has become an innovative therapeutic alternative to current treatments. Paclitaxel-coated balloons (PCB) have been used to treat in-stent restenosis (ISR) and also approach CAD in native arteries. More recently, sirolimus-coated balloons (SCB) are being looked at as part of pilot studies and smaller registries with preliminary results.&nbsp; The<a href="https://solaci.org/en/2023/08/23/eastbourne-registry-use-of-sirolimus-coated-balloons-in-coronary-artery-disease/" title="Read more" >...</a>

Resultados alentadores de los balones cubiertos de Biolimus para el tratamiento de vasos pequeños

PICCOLETO-II: Drug-Coated Balloons in Small Vessels

Use of drug-coated balloons vs. drug-eluting stents in small caliber vessels. The constant advancements in coronary device technology have significantly reduced complication rates (such as that of restenosis). However, there are gaps where a high number of undesirable events prevail, such as small vessel disease (SVD), for which, in previous studies up, the rate of<a href="https://solaci.org/en/2023/04/28/piccoleto-ii-drug-coated-balloons-in-small-vessels/" title="Read more" >...</a>

¿Debemos utilizar balones liberadores de droga en pacientes con enfermedad de múltiples vasos?

Comparative Study of Two Drug Coated Balloons: Angiographic and Clinical Outcomes

The incidence of in-stent restenosis (ISR) requiring repeat revascularization ranges between 5% and 10% of PCI patients receiving new generation drug eluting stents (DES). This is why the current European guidelines on myocardial revascularization recommend treating ISR with drug coated balloons (DCB) with class I recommendation, level of evidence A. DCB are mostly coated with<a href="https://solaci.org/en/2023/04/21/comparative-study-of-two-drug-coated-balloons-angiographic-and-clinical-outcomes/" title="Read more" >...</a>

Resultados a 2 años de los stents liberadores de Zotarolimus vs stents libres de polímero liberadores de Biolimus. ¿Son seguros en pacientes con alto riesgo de sangrado?

Drug-Eluting Balloon in STEACS: Leaving No Trace is Beneficial?

Using drug-eluting balloons in patients with ST-segment elevation acute coronary syndrome. The benefits of early reperfusion in ST-segment elevation acute coronary syndromes (STEACS) have not been discussed; compared with fibrinolysis, primary percutaneous coronary intervention (pPCI) has shown benefits in terms of mortality. Despite the constant advancements in stent technology and design, these devices are not<a href="https://solaci.org/en/2023/04/18/drug-eluting-balloon-in-steacs-leaving-no-trace-is-beneficial/" title="Read more" >...</a>

Top